

## Golimumab Formulation

Version 3.3      Revision Date: 2023/02/23      SDS Number: 26439-00024      Date of last issue: 2023/02/13  
Date of first issue: 2014/10/29

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Golimumab Formulation

#### Supplier's company name, address and phone number

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.  
Menuuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use :  
Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS classification of chemical product

Respiratory sensitisation : Category 1

#### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements : **Prevention:**  
P261 Avoid breathing mist or vapours.  
P284 Wear respiratory protection.  
**Response:**  
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste

---

## Golimumab Formulation

Version 3.3      Revision Date: 2023/02/23      SDS Number: 26439-00024      Date of last issue: 2023/02/13  
 Date of first issue: 2014/10/29

disposal plant.

**Other hazards which do not result in classification**

None known.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Golimumab	476181-74-5	>= 10 - < 20	

**4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 If not breathing, give artificial respiration.  
 If breathing is difficult, give oxygen.  
 Get medical attention.
- In case of skin contact : Wash with water and soap as a precaution.  
 Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).  
 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

**5. FIREFIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
 Sulphur oxides

## Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/02/13
3.3	2023/02/23	26439-00024	Date of first issue: 2014/10/29

- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

#### Handling

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Avoid breathing mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.

## Golimumab Formulation

Version 3.3      Revision Date: 2023/02/23      SDS Number: 26439-00024      Date of last issue: 2023/02/13  
 Date of first issue: 2014/10/29

Avoidance of contact : Take care to prevent spills, waste and minimize release to the environment.  
 Hygiene measures : Oxidizing agents  
 : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 : When using do not eat, drink or smoke.  
 : Wash contaminated clothing before re-use.

**Storage**

Conditions for safe storage : Keep in properly labelled containers.  
 : Keep tightly closed.  
 : Store in accordance with the particular national regulations.  
 Materials to avoid : Do not store with the following product types:  
 : Strong oxidizing agents  
 Packaging material : Unsuitable material: None known.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Reference concentration / Permissible concentration	Basis
Golimumab	476181-74-5	TWA	70 µg/m <sup>3</sup> (OEB 3)	Internal

**Engineering measures** : Ensure adequate ventilation, especially in confined areas.  
 : Minimize workplace exposure concentrations.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
 Filter type : Particulates type  
 Hand protection  
 Material : Chemical-resistant gloves  
 Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.  
 Eye protection : Wear the following personal protective equipment:  
 : Safety glasses  
 Skin and body protection : Skin should be washed after contact.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

**Golimumab Formulation**

Version 3.3      Revision Date: 2023/02/23      SDS Number: 26439-00024      Date of last issue: 2023/02/13  
Date of first issue: 2014/10/29

---

Physical state : Aqueous solution

Colour : opalescent

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit  
Upper explosion limit / Up- : No data available  
per flammability limit

Lower explosion limit / : No data available  
Lower flammability limit

Flash point : No data available

Decomposition temperature : No data available

pH : 5.5

Evaporation rate : No data available

Auto-ignition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Solubility(ies)  
Water solubility : soluble

Partition coefficient: n- : No data available  
octanol/water

Vapour pressure : No data available

Density and / or relative density  
Relative density : No data available

Relative vapour density : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

**Golimumab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/02/13
3.3	2023/02/23	26439-00024	Date of first issue: 2014/10/29

---

Molecular weight : No data available

Particle characteristics  
Particle size : No data available

---

**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : Can react with strong oxidizing agents.  
Conditions to avoid : None known.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Golimumab:**

Exposure routes : Inhalation  
Assessment : May cause sensitisation by inhalation.

**Germ cell mutagenicity**

Not classified based on available information.

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

Not classified based on available information.

## Golimumab Formulation

Version 3.3      Revision Date: 2023/02/23      SDS Number: 26439-00024      Date of last issue: 2023/02/13  
 Date of first issue: 2014/10/29

---

### Components:

#### **Golimumab:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Mouse, male  
 Application Route: Intravenous injection  
 Fertility: NOAEL Parent: 40 mg/kg body weight

Test Type: Fertility/early embryonic development  
 Species: Mouse, female  
 Application Route: Intravenous injection  
 Fertility: NOAEL Parent: 40 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Monkey  
 Teratogenicity: NOAEL: 100 mg/kg body weight  
 Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight

Test Type: Development  
 Species: Monkey  
 Developmental Toxicity: NOAEL F1: 50 mg/kg body weight

Test Type: Embryo-foetal development  
 Species: Mouse  
 Application Route: Intravenous injection  
 Teratogenicity: NOAEL: 40 mg/kg body weight  
 Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight  
 Result: negative, No effects on foetal development

#### **STOT - single exposure**

Not classified based on available information.

#### **STOT - repeated exposure**

Not classified based on available information.

#### **Repeated dose toxicity**

### Components:

#### **Golimumab:**

Species : Monkey  
 NOAEL : 50 mg/kg  
 Application Route : Intravenous  
 Exposure time : 6 Months  
 Number of exposures : Intermittent

Species : Monkey  
 NOAEL : 25 mg/kg  
 Application Route : Subcutaneous  
 Exposure time : 6 Months

Species : Mouse  
 NOAEL : 40 mg/kg  
 Application Route : Intravenous

## Golimumab Formulation

Version 3.3      Revision Date: 2023/02/23      SDS Number: 26439-00024      Date of last issue: 2023/02/13  
Date of first issue: 2014/10/29

---

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Golimumab:**

Inhalation : Symptoms: mild infections, upper respiratory tract infection, viral infections, bronchitis, sinusitis, fungal infections

---

## 12. ECOLOGICAL INFORMATION

**Ecotoxicity****Components:****Golimumab:****Ecotoxicology Assessment**

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

**Persistence and degradability**

No data available

**Bioaccumulative potential**

No data available

**Mobility in soil**

No data available

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

---

## 13. DISPOSAL CONSIDERATIONS

**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

**International Regulations****UNRTDG**

UN number : Not applicable

---



**Golimumab Formulation**

Version 3.3      Revision Date: 2023/02/23      SDS Number: 26439-00024      Date of last issue: 2023/02/13  
Date of first issue: 2014/10/29

---

Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable

**IATA-DGR**

UN/ID No. : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

**IMDG-Code**

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

**Special precautions for user**

Not applicable

---

**15. REGULATORY INFORMATION****Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

**Chemical Substance Control Law**

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

## Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/02/13
3.3	2023/02/23	26439-00024	Date of first issue: 2014/10/29

---

### **Substances Prevented From Impairment of Health**

Not applicable

### **Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

### **Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

### **Substances Subject to be Notified Names**

Not applicable

### **Substances Subject to be Indicated Names**

Not applicable

### **Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

### **Ordinance on Prevention of Lead Poisoning**

Not applicable

### **Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

### **Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

### **Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

### **Poisonous and Deleterious Substances Control Law**

Not applicable

### **Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

### **Until March 31st, 2023**

Not applicable

### **From April 1st, 2023**

Not applicable

### **High Pressure Gas Safety Act**

Not applicable

### **Explosive Control Law**

Not applicable

### **Vessel Safety Law**

Not regulated as a dangerous good

**Golimumab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/02/13
3.3	2023/02/23	26439-00024	Date of first issue: 2014/10/29

---

**Aviation Law**

Not regulated as a dangerous good

**Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

**Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

**Waste Disposal and Public Cleansing Law**

Industrial waste

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**16. OTHER INFORMATION****Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

**Full text of other abbreviations**

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

## Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/02/13
3.3	2023/02/23	26439-00024	Date of first issue: 2014/10/29

---

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN